Showing 10 posts of 10 posts found.

GSK’s Ojjaara approved by FDA for patients with myelofibrosis and anaemia

September 18, 2023
Medical Communications FDA, GSK, Haematology, Ojjaara, anaemia, myelofibrosis

GSK has announced that the US Food and Drug Administration (FDA) has approved Ojjaara (momelotinib) for the treatment of intermediate …


FDA approves BMS’s Reblozyl for treatment of anaemia in adults with lower-risk MDS

August 30, 2023
Research and Development FDA, Haematology, Reblozyl, anaemia, bristol myers squibb, myelodysplastic syndromes

Bristol Myers Squibb (BMS) has announced that the US Food and Drug Administration (FDA) has approved Reblozyl (luspatercept-aamt) for the …


Astellas receives positive CHMP opinion for symptomatic anaemia drug

June 28, 2021
Sales and Marketing Astellas, CKD, anaemia

Astellas and FibroGen have announced that the Committee for Medicinal Products for Human Use (CHMP) of the EMA has adopted …


Japan approves Astellas and FibroGen’s Evrenzo for anaemia in dialysis patients

September 23, 2019
Sales and Marketing Astellas, anaemia, fibrogen, pharma

Astellas Pharma and FibroGen have revealed that their collaborative drug Evrenzo (roxadustat) has secured marketing authorisation in Japan for the …


GSK opens new manufacturing plants in Singapore

July 5, 2019
Manufacturing and Production Asia, HIV, Singapore, anaemia, facilities, manufacturing, pharma

British multinational GlaxoSmithKline has opened two new manufacturing plants in Singapore. The UK firm has also expanded facilities at its …


AstraZeneca scores hat trick in ovarian cancer and anaemia clinical trials

December 20, 2018
Research and Development AstraZeneca, anaemia, oncology, ovarian cancer, pharma

Anglo-Swedish multinational AstraZeneca has revealed that its ovarian cancer drug (Lynparza) and anaemia treatment (Roxadustat) have met their goals in …

GSK reaches endgame of race to develop anaemia drug

November 25, 2016
Research and Development, Sales and Marketing AstraZeneca, Daprodustat, GSK, GlaxoSmithKline, anaemia

GlaxoSmithKline has announced that they will begin Phase 3 development of their anaemia drug, daprodustat. The drug is an oral …


Roche sues Intas Pharma over patent dispute in India

April 18, 2016
Medical Communications, Sales and Marketing India, Roche, anaemia, chronic kidney, intas, intas pharmaceuticals, patent

Roche Pharmaceuticals is suing Indian-based Intas Pharmaceuticals, alleging that the company has infringed upon its patent rights to anaemia drug, …


Keryx Biopharmaceuticals announces positive Phase III study results for anaemia treatment

March 30, 2016
Research and Development CKD, anaemia, chronic kidney disease, clinical trial, dialysis, keryx, keryx biopharmaceuticals, kidney, phase 3, phase III

Keryx Biopharmaceuticals (NASDAQ: KERX) has announced positive top-line results for its Phase III study of ferric citrate for the treatment …


Akebia passes vadadustat for anaemia phase III study with FDA & EMA

October 7, 2015
Research and Development Akabia, FDA, anaemia

Akebia Therapeutics has announced the successful completion of the End-of-Phase II Meeting process with the FDA and the Scientific Advice …

Latest content